Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01200082 · ClinicalTrials.gov registry record

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

A clinical trial, sponsored by University of Nebraska.

Terminated
Registry status
430
Enrollment target

NCT01200082: Clinical Trial study, sponsored by University of Nebraska.

NCT01200082 is a clinical trial that was terminated before completion, run by University of Nebraska. The registered enrollment target is 430 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01200082 was terminated before completion, sponsored by University of Nebraska.

TERMINATED
Registry status
430 participants
Enrollment target

Study Summary

The investigators hypothesize that the extent of sulfation of toxic BAs and their urinary elimination can be used as a biomarker to predict the severity and prognosis of hepatobiliary diseases. The investigators rationale in this project is that the discovery of biomarkers specific to liver injury would provide the foundation for a specific and non-invasive tool to evaluate disease prognosis, determine patients with higher risk of developing end-stage liver diseases, and determine patients with higher risk of recurrence of hepatobiliary complications after liver transplant. Patients on the liver transplant list are continuously monitored during their hospitalization and are scheduled for follow-up visits for 12 months after their release post-surgery. Disease progression will be evaluated by monitoring MELD scores, survival, incidence of liver transplant, and incidence of complications related to hepatobiliary conditions such as fluid retention, GI bleeding, encephalopathy, and biliary stricture complications.

Primary Outcome

Bile acids (BAs), the end products of cholesterol metabolism, are synthesized in liver and excreted into bile, which flows to the small intestine via the bile duct. Most of the BAs are reabsorbed from the intestine into the portal circulation and undergo enterohepatic recirculation with minimal levels detected in urine and blood under normal conditions.

Trial Details

FieldValue
Enrollment Target 430 participants
Start Date 2011-11
Est. Completion 2022-09-02
University of Nebraska

407 total trials

Why NCT01200082 stopped before completion

NCT01200082 is an observational study that tracks outcomes without assigning an intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01200082 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01200082 about?

NCT01200082 is a clinical study titled "Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases". The investigators hypothesize that the extent of sulfation of toxic BAs and their urinary elimination can be used as a biomarker to predict the severity and prognosis of hepatobiliary diseases. The investigators rationale in this project is that the discovery of biomarkers specific to liver injury w...

What is the current status of trial NCT01200082?

This trial is currently terminated. The enrollment target is 430 participants. The study started on 2011-11. Estimated completion is 2022-09-02.

Who is sponsoring clinical trial NCT01200082?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05327023 · 430 participants · Phase 1

    Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

  • NCT05457985 · 430 participants · NA

    Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers

  • NCT05532982 · 430 participants

    Parkinson's Disease in Asian Americans

  • NCT05844891 · 430 participants · NA

    Telehealth-Enhanced Asthma Care for Home After the Emergency Room

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01200082, the US trial registry maintained by the National Library of Medicine. NCT01200082 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.